Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(1.76)
# 3,152
Out of 4,761 analysts
48
Total ratings
24.39%
Success rate
-2.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $11.02 | - | 3 | Jan 21, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $7.68 | - | 6 | Jan 14, 2025 | |
| ATYR aTyr Pharma | Initiates: Overweight | n/a | $4.32 | - | 1 | Jan 6, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $5.77 | +73.31% | 1 | Dec 17, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $336.23 | - | 4 | Nov 20, 2024 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $23.77 | +173.51% | 12 | Sep 23, 2024 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Overweight | n/a | $42.33 | - | 10 | Sep 23, 2024 | |
| AKRO Akero Therapeutics | Reiterates: Overweight | n/a | $51.84 | - | 5 | Jun 20, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Neutral | n/a | $1.25 | - | 2 | Feb 20, 2024 | |
| TGTX TG Therapeutics | Reiterates: Overweight | $24 | $30.88 | -22.28% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $1.68 | +26,685.71% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $0.88 | +1,490.91% | 1 | Mar 3, 2021 |
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $11.02
Upside: -
ORIC Pharmaceuticals
Jan 14, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.68
Upside: -
aTyr Pharma
Jan 6, 2025
Initiates: Overweight
Price Target: n/a
Current: $4.32
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $5.77
Upside: +73.31%
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $336.23
Upside: -
Structure Therapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: $65
Current: $23.77
Upside: +173.51%
MoonLake Immunotherapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $42.33
Upside: -
Akero Therapeutics
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $51.84
Upside: -
RAPT Therapeutics
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.25
Upside: -
TG Therapeutics
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $30.88
Upside: -22.28%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $1.68
Upside: +26,685.71%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $0.88
Upside: +1,490.91%